Abstract

DIABETES MELLITUS AND COVID.19 RETROSPECTIVE OBSERVATIONAL STUDY

Khleel Tweek Bardan*

ABSTRACT

Among the risk factors for severe disease and mortality caused by COVID-19, diabetes has emerged as a key one. Few data exist on how COVID-19 patients with diabetes and acute hyperglycemia fare in hospitals. This was a retrospective observational study that looked at the glycemic and clinical outcomes for adults with lab-confirmed cases of COVID-19. hospitalisation results in 2020 for patients with and without diabetes and/or acute uncontrolled hyperglycemia. An A1C level of 6.5% or higher was used as the diagnostic threshold for diabetes. Two or more blood glucose (BG) readings that were higher than 180 mg/dL were considered to be clinically significant indicators of uncontrolled hyperglycemia. dL in the course of a day. The data were extracted from Glytec's data centre. Methods: Hospitalized patients with diabetes and/or uncontrolled hyperglycemia spent an average of an extra Over three-and-a-half percent of patient days had mean BG > 180 mg/dL. The mortality rate was calculated from all admitted patients, including those who died and those who were released. Results: was 28.8% in those with diabetes and/or uncontrolled hyperglycemia and only 6.2% in those without diabetes or elevated blood sugar (P .001). Among the diabetic and/or hyperglycemic patients who passed away or were released from the hospital, More patients with uncontrolled hyperglycemia (41.7%) passed away than those with diabetes (14.8%) (P .001). The median length of stay (LOS) was lengthened in 184 patients with diabetes and/or uncontrolled hypertension among 493 discharged survivors. individuals with diabetes or hyperglycemia (5.7 vs. 4.3 days, P .001), respectively.

Keywords: COVID-19; Diabetes; Glucose; Glytec; Hospital; Hyperglycemia; Length of Stay; Mortality.